Edwards Presents (TRISCEND) Study Results of EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation at PCR 2022
Shots:
- The company reported the 1yr. results from the (TRISCEND) study evaluating EVOQUE transcatheter tricuspid valve replacement system in 176 patients with tricuspid regurgitation. Enrolled patients had symptomatic mod. or greater functional or degenerative TR, despite optimal medical therapy
- The results showed a favorable safety, efficacy & QoL outcome, 90.1% high survival and high freedom from HF hospitalization at 88.4%; significant and sustained TR reduction with 97.6% with mild or trace TR, 93% of patients in NYHA Class I or II vs 26% at baseline and a 26-point increase in KCCQ score
- The system demonstrated a persistent improvement in symptom status and low rates of mortality & HF hospitalizations @1yr. follow-up
Ref: PRNewswire | Image: Edwards
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
